On September 17, the Endocrine Society will mobilize a delegation of its leading member researchers to Washington, D.C., to participate in the fourteenth annual Rally for Medical Research Hill Day. This high-profile advocacy event brings together a broad coalition of hundreds of research organizations, professional scientific societies, and patient advocacy groups with a unified mission: to urge Congress to prioritize and increase funding for the National Institutes of Health (NIH) in the final federal appropriations legislation. As the federal fiscal year draws to a close, the scientific community is making a concerted push for a budget of $51.3 billion for the NIH, a figure deemed essential by experts to sustain the momentum of medical breakthroughs and maintain the United States’ global leadership in biomedical innovation.
The timing of this year’s Hill Day is critical, occurring just weeks before the October 1 start of the new federal fiscal year. The Endocrine Society’s participation underscores the vital role that endocrine research plays in addressing some of the most pressing public health challenges, including diabetes, obesity, thyroid disorders, and hormone-related cancers. By joining forces with the wider medical community, the Society aims to provide lawmakers with firsthand accounts of how federal investment translates into life-saving treatments and economic stability for communities across the nation.
The Legislative Landscape: Continuing Resolutions and the Lame Duck Session
The push for increased NIH funding occurs against a backdrop of significant legislative complexity. Congress is constitutionally required to pass all twelve annual appropriations bills before the start of the fiscal year on October 1 to prevent a government shutdown. However, as of mid-September, both the House of Representatives and the Senate have acknowledged that they will not meet this deadline. In response, each chamber has moved toward passing a short-term funding measure known as a Continuing Resolution (CR).
A CR typically maintains government spending at the previous year’s levels for a specific duration—in this case, until December. This tactical move allows the federal government to remain operational while postponing final budgetary decisions until after the November midterm elections. This post-election period, commonly referred to as a “lame duck” session, is when the House and Senate are expected to reconcile their different versions of the appropriations bills and pass a final, comprehensive funding package.
For the Endocrine Society and its partners, the CR represents both a challenge and an opportunity. While a CR prevents a shutdown, it also creates a period of budgetary stagnation where new research initiatives may be delayed and existing grants may face uncertainty. The September 17 Hill Day serves as a timely reminder to legislators that while temporary measures keep the doors open, only a substantial and predictable increase in the final appropriations bill will allow the NIH to fulfill its long-term mission of improving human health.
The Economic and Scientific Case for $51.3 Billion
The request for $51.3 billion for the NIH is not an arbitrary figure; it is based on an assessment of the current scientific landscape and the inflationary pressures facing research institutions. According to data from United for Medical Research (UMR), the NIH is a primary driver of economic activity. In fiscal year 2023, NIH funding supported more than 412,000 jobs and generated approximately $92.89 billion in economic activity nationwide. On average, every $1 of NIH funding generates roughly $2.46 in local economic growth, making medical research one of the most efficient uses of federal taxpayer dollars.
Beyond the economic impact, the scientific necessity for increased funding is driven by the rising costs of laboratory equipment, specialized personnel, and the increasing complexity of clinical trials. The Biomedical Research and Development Price Index (BRDPI), which measures the change in the price of goods and services purchased through NIH-funded research, has consistently shown that the cost of doing science rises faster than general consumer inflation. Without a significant budget increase, the “purchasing power” of the NIH effectively declines, leading to fewer grants being awarded and a potential "brain drain" as young researchers seek opportunities in more stable sectors or abroad.
For the endocrine community specifically, NIH funding is the lifeblood of discovery. Research into the endocrine system—the complex network of glands and hormones that regulate nearly every bodily function—is essential for managing chronic conditions that affect millions of Americans. For instance, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) relies on NIH appropriations to fund research into preventing type 2 diabetes and finding a cure for type 1 diabetes. Similarly, research into endocrine-disrupting chemicals (EDCs) and their impact on reproductive health and developmental biology is largely dependent on federal grants.
A History of Impact: The Rally for Medical Research
Now in its fourteenth year, the Rally for Medical Research has become a cornerstone of the scientific community’s advocacy efforts. The event was established to provide a unified voice for the thousands of stakeholders who depend on NIH funding. Historically, the rally has been credited with helping to reverse the trend of stagnant or declining NIH budgets that characterized the early 2010s. By bringing together diverse groups—from oncologists and neurologists to rare disease advocates and basic scientists—the rally demonstrates to Congress that medical research is a non-partisan issue with broad public support.
The "Hill Day" component of the rally involves scheduled meetings between researchers and their respective congressional representatives and senators. During these meetings, scientists share data-driven arguments alongside personal stories of how their research impacts constituents. For the Endocrine Society, this means highlighting local laboratories that employ residents, hospitals that provide cutting-edge endocrine care, and the long-term cost savings associated with preventing chronic endocrine diseases through research-led interventions.
Analysis of Implications: The Risk of an Innovation Gap
The consequences of failing to secure a robust increase for the NIH extend beyond the immediate fiscal year. Policy analysts warn of a potential "innovation gap" if the U.S. does not maintain a competitive funding environment. Other nations, particularly in Asia and Europe, have significantly increased their domestic investments in biotechnology and life sciences. If NIH funding remains flat or fails to keep pace with inflation, the U.S. risks losing its status as the global hub for medical innovation.
Furthermore, the stability of the research workforce is at stake. The process of becoming an independent, NIH-funded investigator takes years of rigorous training. When funding becomes unpredictable, early-career researchers are often the first to be affected, leading many to abandon academic research. This loss of talent can stall scientific progress for decades. The Endocrine Society’s advocacy emphasizes that a $51.3 billion budget is an investment in the next generation of scientists who will tackle future pandemics, aging-related diseases, and the ongoing obesity epidemic.
The "lame duck" session in November will be the final arena for these budgetary battles. Historically, these sessions can be unpredictable, as outgoing members of Congress and those newly re-elected negotiate the final details of massive "omnibus" spending bills. The presence of the research community in D.C. this September is designed to ensure that NIH funding remains a top-tier priority when those final negotiations occur.
Digital Advocacy and the Role of the Scientific Community
Recognizing that not all researchers can travel to the nation’s capital, the Endocrine Society has launched a comprehensive online advocacy campaign to complement the in-person Hill Day. This digital initiative allows U.S.-based members to contact their representatives and senators through a streamlined portal. By entering their contact information, members can send pre-drafted, evidence-based messages urging lawmakers to support the $51.3 billion funding target.
The Society emphasizes that constituent outreach is one of the most effective ways to influence congressional behavior. Lawmakers are highly sensitive to the concerns of the people they represent, and hearing from a constituent who is a doctor or a researcher in their home district carries significant weight. The online campaign ensures that the message delivered on September 17 is amplified by thousands of voices across the country, creating a steady drumbeat of support for the NIH.
Conclusion: The Path Forward for American Medical Research
As the Endocrine Society joins its colleagues for the Rally for Medical Research Hill Day, the objective is clear: to secure a future where medical discovery is limited only by the imagination of scientists, not by the constraints of a stagnant budget. The request for $51.3 billion for the NIH represents a commitment to public health, economic prosperity, and scientific excellence.
The upcoming weeks will be a defining period for federal science policy. While the passage of a Continuing Resolution is a necessary step to keep the government functioning, the ultimate goal remains the enactment of a final appropriations bill that reflects the true value of medical research. Through direct engagement with policymakers and a robust digital advocacy strategy, the Endocrine Society and its partners are working to ensure that the vital work of understanding and treating the human endocrine system continues to move forward without interruption. The results of these efforts will be felt not only in the laboratories of today but in the clinics and hospitals of tomorrow, where the breakthroughs of the future are currently waiting to be discovered.
